Developer docs
API playgroundTry for free, no card

Search company profiles

Vanqua Bio

Full company profile

uuid0000p8k

Namestring
Vanqua Bio
Legal namestring
Vanqua Bio, Inc.
Websiteurl
vanquabio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Vanqua Bio is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Chicago, IL. The company discovers and develops small-molecule therapies for neurodegenerative and neuroinflammatory diseases, with its primary focus on genetically defined forms of Parkinson's disease (GBA-PD), Dementia with Lewy Bodies, and Gaucher disease. Its lead asset, VQ-101, is an oral, brain-penetrant allosteric activator of glucocerebrosidase (GCase) designed to restore lysosomal function in neurons carrying GBA1 mutations. The pipeline also includes C5aR1 antagonist compounds targeting complement-mediated neuroinflammation in CNS and peripheral indications.

Vanqua's drug discovery platform is built on patient-derived induced pluripotent stem cell (iPSC) neuronal models, grounded in the academic work of scientific founder Dimitri Krainc at Northwestern University. This platform supports target validation and lead optimization in disease-relevant human cell types. VQ-101 has progressed into Phase 1b clinical evaluation, with positive interim data reported in late 2025.

The company operates a licensing- and milestone-driven business model rather than a commercial one. It has no approved products and no product revenue; capital is sourced from private equity financing rounds led by healthcare-focused institutional investors, and non-dilutive capital is generated through partnership transactions — most notably the October 2025 license of its C5aR1 antagonist program to Biogen for $70M upfront and up to $990M in potential milestones.

Short descriptiontext

Vanqua Bio is a Chicago-based clinical-stage biopharmaceutical company developing oral small-molecule therapies for neurodegenerative diseases, including GCase activators for Parkinson's (GBA-PD) and C5aR1 antagonists for neuroinflammation, monetized through licensing and milestone deals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative disease therapeutics, GCase activator drugs, Parkinson's disease treatment, complement pathway modulators, biopharmaceutical drug discovery
Industry1 code
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals — Neurodegenerative Disease Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Revenue
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotech company. Generating revenue through licensing deals with pharmaceutical partners. In October 2025, Vanqua Bio received $70 million upfront payment from Biogen for licensing exclusive worldwide rights to its preclinical oral C5aR1 antagonist, with potential additional milestone payments of up to $990 million.

sec.gov
2Future Product Revenue
TypeOne Time License
Description

Once clinical candidates receive regulatory approval, the company will pursue commercialization of novel therapeutics for neurodegenerative diseases, targeting Parkinson's disease, Dementia with Lewy Bodies, and other neurological disorders.

marketscreener.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vanqua Bio is a clinical-stage biopharmaceutical company that discovers and develops small-molecule medicines for neurodegenerative diseases, anchored by VQ-101, an oral, brain-penetrant allosteric activator of glucocerebrosidase (GCase) in Phase 1b development for GBA-Parkinson's disease and related disorders. The company also develops C5aR1 antagonists targeting complement-mediated inflammation, with the peripheral program (VQ-201) licensed to Biogen and CNS-penetrant C5aR1 candidates retained for neuroinflammation. Discovery is enabled by a proprietary patient iPSC-derived neuronal cell screening platform combined with allosteric activator chemistry.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Vanqua Bio is a clinical-stage biopharmaceutical company with two core therapeutic programs: VQ-101, an oral brain-penetrant allosteric activator of GCase currently in Phase 1b clinical trials for Parkinson's disease, and a C5aR1 antagonist program (including VQ-201 for peripheral indications and CNS-penetrant candidates) that was licensed to Biogen in 2025. The company's discovery platform utilizes patient-derived iPSC neurons to identify novel small-molecule therapies targeting lysosomal dysfunction and innate immune system overactivation in neurodegenerative and inflammatory diseases.

Product and service3 records
1VQ-101
CategoryClinical-stage small-molecule therapeutic (GCase activator)
Description

An orally administered, fully brain-penetrant small-molecule allosteric activator of glucocerebrosidase (GCase) for the treatment of GBA-Parkinson's disease, idiopathic Parkinson's disease, Dementia with Lewy Bodies, and all forms of Gaucher disease. Designed to restore GCase activity to healthy levels and block accumulation of pathological alpha-synuclein. First small molecule to demonstrate >75% activation of lysosomal GCase in humans, with full CNS penetrance (CSF:unbound plasma ratios ≥1) and projected once-daily oral dosing.

2VQ-201
CategoryPre-clinical small-molecule therapeutic (C5aR1 antagonist)
Description

A next-generation allosteric small-molecule C5aR1 antagonist targeting complement-mediated inflammation for peripheral inflammatory disorders. Demonstrated robust blockade of C5a-mediated chemotaxis and activation of pathogenic immune cells, with renal protection in preclinical models. Licensed to Biogen in October 2025 for exclusive worldwide development and commercialization rights.

3CNS-penetrant C5aR1 antagonist program
CategoryEarly-stage small-molecule therapeutic program (CNS-penetrant C5aR1 antagonist)
Description

First-in-class CNS-penetrant C5aR1 antagonists targeting neuroinflammation in central nervous system disorders, including Alzheimer's disease. Designed to reduce pathogenic complement-mediated activation of CNS immune cells and slow disease progression. Retained by Vanqua Bio as part of its CNS-focused pipeline following the Biogen licensing of the peripheral C5aR1 program.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-24
Description

Vanqua Bio entered an exclusive worldwide licensing agreement with Biogen for Vanqua's preclinical oral C5aR1 antagonist program. Biogen received rights to develop and commercialize the peripherally-directed compound for inflammatory diseases. Vanqua received $70 million upfront payment and is eligible for up to $990 million in development, regulatory, commercial, and sales milestone payments, plus tiered royalties on potential net sales. Biogen plans to advance the program into clinical development with an IND filing expected in 2027. This deal marks Biogen's first pipeline acquisition in 2025 and strengthens their immunology portfolio.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical research organization in the Netherlands conducting Vanqua Bio's Phase 1 clinical trial of VQ-101. The Phase 1a portion was conducted at CHDR facilities, evaluating safety, pharmacokinetics, and pharmacodynamics in healthy volunteers.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Foundational research partner. Technology platform based on seminal research by Dimitri Krainc, MD, PhD, Chair of Neurology at Northwestern University's Feinberg School of Medicine. Dr. Krainc chairs Vanqua Bio's Scientific Advisory Board and is a co-founder. Company founded in proximity to Northwestern's world-renowned Krainc Laboratory.

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Gene therapy biotech targeting CNS diseases including Parkinson's. Comparable neuroscience focus and disease-modifying thesis but uses AAV gene therapy rather than Vanqua Bio's small-molecule approach.

TypeDirect peer
Description

Clinical-stage biotech developing small-molecule therapies for neurodegenerative diseases including Parkinson's and lysosomal storage disorders. Directly comparable to Vanqua Bio given shared GBA-PD focus, CNS-penetrant small-molecule strategy, and patient-derived iPSC discovery approach.

TypeDirect peer
Description

Clinical-stage neurodegeneration biotech with programs targeting lysosomal function and neuroinflammation for Parkinson's and Alzheimer's. Comparable business model, stage, and neurodegenerative focus; both companies emerged from elite academic neuroscience labs with similar financing syndicates.

TypeDirect peer
Description

Acquired by Eli Lilly in 2020 to develop AAV gene therapies for Parkinson's and other CNS disorders, including a GBA1 program. Most direct GBA-PD peer; contrasts with Vanqua Bio's small-molecule allosteric activator approach.

TypeDirect peer
Description

Clinical-stage CNS biopharma developing brain-penetrant small molecules for neurological disorders. Comparable in stage, CNS small-molecule discovery approach, and partnership-driven business model (e.g., Zurzuvae collaboration with Biogen).

TypeDirect peer
Description

Clinical-stage muscle and CNS biotech; CSO Kevin Hunt previously served as Executive Director of Drug Discovery at Edgewise. Comparable in stage, therapeutic modality (small molecules), and CNS focus area.

TypeEmerging player
Description

Late-stage clinical biotech targeting alpha-synuclein for Parkinson's disease. Pursues a different therapeutic modality (antibodies) but addresses the same synucleinopathy pathology underlying Vanqua Bio's GCase activator mechanism.

TypeEmerging player
Description

CNS-focused clinical-stage biotech developing small molecules for neuroscience indications including Parkinson's. Comparable in stage, modality, and CNS small-molecule discovery, though broader in therapeutic area than Vanqua Bio.

9Yumanity Therapeutics
TypeEmerging player
Description

Clinical-stage biotech developing disease-modifying therapies for Parkinson's and related neurodegenerative diseases. Comparable in disease focus and stage but pursued protein-misfolding-based targets rather than GCase activation.

TypeEmerging player
Description

Clinical-stage gene therapy biotech with CNS programs including for GBA-Parkinson's. Comparable in stage and GBA1 disease focus, applying AAV gene therapy as an alternative modality to Vanqua Bio's small-molecule activators.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vanqua Bio

Biopharmaceuticals — Neurodegenerative Disease Therapeuticsvanquabio.com

Vanqua Bio is a Chicago-based clinical-stage biopharmaceutical company developing oral small-molecule therapies for neurodegenerative diseases, including GCase activators for Parkinson's (GBA-PD) and C5aR1 antagonists for neuroinflammation, monetized through licensing and milestone deals.

What Vanqua Bio does

Vanqua Bio is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Chicago, IL. The company discovers and develops small-molecule therapies for neurodegenerative and neuroinflammatory diseases, with its primary focus on genetically defined forms of Parkinson's disease (GBA-PD), Dementia with Lewy Bodies, and Gaucher disease. Its lead asset, VQ-101, is an oral, brain-penetrant allosteric activator of glucocerebrosidase (GCase) designed to restore lysosomal function in neurons carrying GBA1 mutations. The pipeline also includes C5aR1 antagonist compounds targeting complement-mediated neuroinflammation in CNS and peripheral indications.

Vanqua's drug discovery platform is built on patient-derived induced pluripotent stem cell (iPSC) neuronal models, grounded in the academic work of scientific founder Dimitri Krainc at Northwestern University. This platform supports target validation and lead optimization in disease-relevant human cell types. VQ-101 has progressed into Phase 1b clinical evaluation, with positive interim data reported in late 2025.

The company operates a licensing- and milestone-driven business model rather than a commercial one. It has no approved products and no product revenue; capital is sourced from private equity financing rounds led by healthcare-focused institutional investors, and non-dilutive capital is generated through partnership transactions — most notably the October 2025 license of its C5aR1 antagonist program to Biogen for $70M upfront and up to $990M in potential milestones.

Vanqua Bio firmographics

Firmographics
Name
Vanqua Bio
Legal name
Vanqua Bio, Inc.
Website
https://vanquabio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Vanqua Bio is a Chicago-based clinical-stage biopharmaceutical company developing oral small-molecule therapies for neurodegenerative diseases, including GCase activators for Parkinson's (GBA-PD) and C5aR1 antagonists for neuroinflammation, monetized through licensing and milestone deals.
Ownership category
akta.pro rank

Vanqua Bio industry classification

Industry
Product category
Biopharmaceuticals — Neurodegenerative Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Neurodegenerative disease therapeutics
  • GCase activator drugs
  • Parkinson's disease treatment
  • Complement pathway modulators
  • Biopharmaceutical drug discovery

Where Vanqua Bio is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Vanqua Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Licensing and Milestone Revenue: Pre-revenue clinical-stage biotech company. Generating revenue through licensing deals with pharmaceutical partners. In October 2025, Vanqua Bio received $70 million upfront payment from Biogen for licensing exclusive worldwide rights to its preclinical oral C5aR1 antagonist, with potential additional milestone payments of up to $990 million.
  2. Future Product Revenue: Once clinical candidates receive regulatory approval, the company will pursue commercialization of novel therapeutics for neurodegenerative diseases, targeting Parkinson's disease, Dementia with Lewy Bodies, and other neurological disorders.

Go-to-market motion1 record

Marketing channels4 records

Vanqua Bio product offering

Product offering

Core offering

Vanqua Bio is a clinical-stage biopharmaceutical company that discovers and develops small-molecule medicines for neurodegenerative diseases, anchored by VQ-101, an oral, brain-penetrant allosteric activator of glucocerebrosidase (GCase) in Phase 1b development for GBA-Parkinson's disease and related disorders. The company also develops C5aR1 antagonists targeting complement-mediated inflammation, with the peripheral program (VQ-201) licensed to Biogen and CNS-penetrant C5aR1 candidates retained for neuroinflammation. Discovery is enabled by a proprietary patient iPSC-derived neuronal cell screening platform combined with allosteric activator chemistry.

Product overview

Vanqua Bio is a clinical-stage biopharmaceutical company with two core therapeutic programs: VQ-101, an oral brain-penetrant allosteric activator of GCase currently in Phase 1b clinical trials for Parkinson's disease, and a C5aR1 antagonist program (including VQ-201 for peripheral indications and CNS-penetrant candidates) that was licensed to Biogen in 2025. The company's discovery platform utilizes patient-derived iPSC neurons to identify novel small-molecule therapies targeting lysosomal dysfunction and innate immune system overactivation in neurodegenerative and inflammatory diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • VQ-101 An orally administered, fully brain-penetrant small-molecule allosteric activator of glucocerebrosidase (GCase) for the treatment of GBA-Parkinson's disease, idiopathic Parkinson's disease, Dementia with Lewy Bodies, and all forms of Gaucher disease. Designed to restore GCase activity to healthy levels and block accumulation of pathological alpha-synuclein. First small molecule to demonstrate >75% activation of lysosomal GCase in humans, with full CNS penetrance (CSF:unbound plasma ratios ≥1) and projected once-daily oral dosing.
  • VQ-201 A next-generation allosteric small-molecule C5aR1 antagonist targeting complement-mediated inflammation for peripheral inflammatory disorders. Demonstrated robust blockade of C5a-mediated chemotaxis and activation of pathogenic immune cells, with renal protection in preclinical models. Licensed to Biogen in October 2025 for exclusive worldwide development and commercialization rights.
  • CNS-penetrant C5aR1 antagonist program First-in-class CNS-penetrant C5aR1 antagonists targeting neuroinflammation in central nervous system disorders, including Alzheimer's disease. Designed to reduce pathogenic complement-mediated activation of CNS immune cells and slow disease progression. Retained by Vanqua Bio as part of its CNS-focused pipeline following the Biogen licensing of the peripheral C5aR1 program.

Companies that use Vanqua Bio

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Vanqua Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Vanqua Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Biogen Inc.coreStrategic or Co-development Partner · 24 October 2025Vanqua Bio entered an exclusive worldwide licensing agreement with Biogen for Vanqua's preclinical oral C5aR1 antagonist program. Biogen received rights to develop and commercialize the peripherally-directed compound for inflammatory diseases. Vanqua received $70 million upfront payment and is eligible for up to $990 million in development, regulatory, commercial, and sales milestone payments, plus tiered royalties on potential net sales. Biogen plans to advance the program into clinical development with an IND filing expected in 2027. This deal marks Biogen's first pipeline acquisition in 2025 and strengthens their immunology portfolio.
  • Centre for Human Drug Research (CHDR)coreStrategic or Co-development PartnerClinical research organization in the Netherlands conducting Vanqua Bio's Phase 1 clinical trial of VQ-101. The Phase 1a portion was conducted at CHDR facilities, evaluating safety, pharmacokinetics, and pharmacodynamics in healthy volunteers.
  • Northwestern University / Krainc LaboratorycoreStrategic or Co-development PartnerFoundational research partner. Technology platform based on seminal research by Dimitri Krainc, MD, PhD, Chair of Neurology at Northwestern University's Feinberg School of Medicine. Dr. Krainc chairs Vanqua Bio's Scientific Advisory Board and is a co-founder. Company founded in proximity to Northwestern's world-renowned Krainc Laboratory.

Scale indicators5 records

Expansion highlights5 records

Vanqua Bio competitors and assessment

Company assessment

Emerging players

  • Voyager Therapeutics: Gene therapy biotech targeting CNS diseases including Parkinson's. Comparable neuroscience focus and disease-modifying thesis but uses AAV gene therapy rather than Vanqua Bio's small-molecule approach.
  • Prothena Corporation: Late-stage clinical biotech targeting alpha-synuclein for Parkinson's disease. Pursues a different therapeutic modality (antibodies) but addresses the same synucleinopathy pathology underlying Vanqua Bio's GCase activator mechanism.
  • Cerevel Therapeutics: CNS-focused clinical-stage biotech developing small molecules for neuroscience indications including Parkinson's. Comparable in stage, modality, and CNS small-molecule discovery, though broader in therapeutic area than Vanqua Bio.
  • Yumanity Therapeutics: Clinical-stage biotech developing disease-modifying therapies for Parkinson's and related neurodegenerative diseases. Comparable in disease focus and stage but pursued protein-misfolding-based targets rather than GCase activation.
  • Lexeo Therapeutics: Clinical-stage gene therapy biotech with CNS programs including for GBA-Parkinson's. Comparable in stage and GBA1 disease focus, applying AAV gene therapy as an alternative modality to Vanqua Bio's small-molecule activators.

Direct peers

  • Denali Therapeutics: Clinical-stage biotech developing small-molecule therapies for neurodegenerative diseases including Parkinson's and lysosomal storage disorders. Directly comparable to Vanqua Bio given shared GBA-PD focus, CNS-penetrant small-molecule strategy, and patient-derived iPSC discovery approach.
  • Alector: Clinical-stage neurodegeneration biotech with programs targeting lysosomal function and neuroinflammation for Parkinson's and Alzheimer's. Comparable business model, stage, and neurodegenerative focus; both companies emerged from elite academic neuroscience labs with similar financing syndicates.
  • Prevail Therapeutics (Eli Lilly): Acquired by Eli Lilly in 2020 to develop AAV gene therapies for Parkinson's and other CNS disorders, including a GBA1 program. Most direct GBA-PD peer; contrasts with Vanqua Bio's small-molecule allosteric activator approach.
  • Sage Therapeutics: Clinical-stage CNS biopharma developing brain-penetrant small molecules for neurological disorders. Comparable in stage, CNS small-molecule discovery approach, and partnership-driven business model (e.g., Zurzuvae collaboration with Biogen).
  • Edgewise Therapeutics: Clinical-stage muscle and CNS biotech; CSO Kevin Hunt previously served as Executive Director of Drug Discovery at Edgewise. Comparable in stage, therapeutic modality (small molecules), and CNS focus area.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Vanqua Bio social profiles

Digital presence

Vanqua Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vanqua Bio leadership team

Management profile

Number of profiles

Profiles12 records

Vanqua Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vanqua Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vanqua Bio

What does Vanqua Bio do?

Vanqua Bio is a clinical-stage biopharmaceutical company that discovers and develops small-molecule medicines for neurodegenerative diseases, anchored by VQ-101, an oral, brain-penetrant allosteric activator of glucocerebrosidase (GCase) in Phase 1b development for GBA-Parkinson's disease and related disorders. The company also develops C5aR1 antagonists targeting complement-mediated inflammation, with the peripheral program (VQ-201) licensed to Biogen and CNS-penetrant C5aR1 candidates retained for neuroinflammation. Discovery is enabled by a proprietary patient iPSC-derived neuronal cell screening platform combined with allosteric activator chemistry.

Is Vanqua Bio a public or private company?

Vanqua Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vanqua Bio founded?

Vanqua Bio was founded in 2019. It employs 11 to 50 people.

Where is Vanqua Bio based?

Vanqua Bio is headquartered in Chicago, United States, in the North America region.

How does Vanqua Bio make money?

Two revenue lines are on record. Licensing and Milestone Revenue is the primary driver. The others are future Product Revenue.

Who are Vanqua Bio's main competitors?

Emerging players on record are Voyager Therapeutics, Prothena Corporation, Cerevel Therapeutics, Yumanity Therapeutics and Lexeo Therapeutics. Direct peers are Denali Therapeutics, Alector, Prevail Therapeutics (Eli Lilly), Sage Therapeutics and Edgewise Therapeutics.

Does Vanqua Bio have an API?

No public API is recorded for Vanqua Bio.

What industry is Vanqua Bio in?

Vanqua Bio's product category is Biopharmaceuticals — Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireVanqua Bio to Present Positive Biomarker Data from Ongoing Phase 1b Study at Upcoming Medical ConferencesVanqua Bio announced it will present positive interim biomarker data from its Phase 1b study of VQ-101, an allosteric activator of lysosomal glucocerebrosidase, at the World Parkinson's Congress and GBA1 Meeting 2026 in Phoenix, Arizona. The Phase 1b results showed that VQ-101 achieved robust peripheral and central exposure, was well tolerated, and demonstrated sustained activation of lysosomal GCase in patients with Parkinson's disease, with and without GBA1 mutations. The company's open-label extension portion of the trial is expected to be completed mid-2026.ParkinsonsnewstodayAAN 2026: VQ-101 reaches brain, its target in Parkinson’s patientsA new oral therapy named VQ-101 has been shown to effectively reach the brain and increase the activity of the protective protein glucocerebrosidase in Parkinson’s disease patients, according to results from a Phase 1 study conducted by Vanqua Bio. The study demonstrated that VQ-101 raised enzyme levels significantly, with results suggesting it could become a leading treatment option for both GBA-associated and idiopathic forms of Parkinson’s. Vanqua Bio is planning further clinical trials to continue evaluating the therapy's efficacy.GlobeNewswireVanqua Bio to Present at the AD/PD™ 2026 International ConferenceVanqua Bio will present interim results from its Phase 1 trial of VQ-101 at the AD/PD 2026 conference in Copenhagen on March 20. The data show sustained activation of lysosomal GCase by over 50% in Parkinson's patients, exceeding the study's target engagement goal. The open-label extension is expected to complete in mid-2026.TaylorwessingBiopharma partnering update: Q4 2025The Q4 2025 biopharma partnering update highlights several significant licensing and collaboration deals, with Takeda Pharmaceutical and Innovent Biologics announcing the quarter's landmark agreement worth up to US$11.4 billion for three solid tumor drug candidates including the antibody-drug conjugate IBI343 and immuno-oncology drug IBI363. Other notable deals include Zenas BioPharma's global licensing agreement with InnoCare Pharma for BTK inhibitor Orelabrutinib (valued over US$2 billion), Novartis partnering with Relation Therapeutics on AI-enabled discovery for atopic diseases (up to US$1.7 billion), Biogen acquiring rights to Vanqua Bio's C5aR1 antagonist (nearly US$1 billion), and Zealand Pharma collaborating with OTR Therapeutics for oral metabolic disease therapeutics (up to US$2.5 billion).GlobeNewswireBiogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology PortfolioBiogen licensed Vanqua Bio's oral C5aR1 antagonist for inflammatory diseases, granting exclusive worldwide rights. Vanqua received $70 million upfront and up to $990 million in milestones, with Biogen planning an IND filing in 2027 if results are supportive.GlobeNewswireBiogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology PortfolioBiogen and Vanqua Bio announced a license agreement on October 24, 2025, granting Biogen exclusive worldwide rights to Vanqua's preclinical oral C5aR1 antagonist for treating inflammatory disorders. Vanqua will receive a $70 million upfront payment and up to $990 million in potential milestone and royalty payments. Biogen will lead all future development, manufacturing, and commercialization efforts, with plans to file an Investigational New Drug application in 2027 if preclinical results continue to be supportive.BenzingaBiogen's Immunology Pipeline Has Long-Term Potential: Analyst - Biogen (NASDAQ:BIIB)Biogen announced a license agreement with Vanqua Bio to gain exclusive rights to Vanqua's preclinical oral C5aR1 antagonist, aiming to enhance its immunology pipeline. The program has shown promising preclinical results and could move into clinical development with an IND filing targeted for 2027. The deal involves upfront payments and potential milestones, with Biogen leading all development efforts.MarketScreenerBiogen Gets Worldwide Rights to Vanqua Bio's Preclinical Drug Candidate for Inflammatory DisordersBiogen has acquired worldwide rights to Vanqua Bio's preclinical drug candidate for inflammatory disorders. The deal expands Biogen's portfolio in therapeutic products and partnerships.MarketScreenerBiogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology PortfolioBiogen has entered into a license agreement with Vanqua Bio, gaining exclusive worldwide rights to Vanqua's preclinical oral C5aR1 antagonist designed to modulate neutrophil-driven inflammation across a range of inflammatory disorders. Vanqua will receive a $70 million upfront payment with potential development, regulatory, commercial, and sales milestone payments of up to $990 million, plus tiered royalties on net sales, while Biogen will lead all future development, manufacturing, and commercialization efforts. Biogen expects to file an Investigational New Drug application in 2027 pending supportive results.